Skip to main content
padlock icon - secure page this page is secure

Prolonged course of pure red cell aplasia after erythropoietin therapy

Buy Article:

$59.00 + tax (Refund Policy)

Nigg L, Schanz U, Ambühl PM, Fehr J, Bachli EB. Prolonged course of pure red cell aplasia after erythropoietin therapy. Eur J Haematol 2004: 73: 376–379. © Blackwell Munksgaard 2004. Abstract: 

Pure red cell aplasia (PRCA) caused by neutralising anti-erythropoietin antibodies is a very rare disease. Since 1998, an increased incidence of PRCA in patients with kidney failure following treatment with recombinant human erythropoietin (rhEpo) has been reported, mostly in Europe. In most cases, PRCA was cured by immunosuppressive therapy, immunoglobulins, plasmapheresis or renal transplantation. We report an exceptionally prolonged course of PRCA over 68 months despite renal transplantation and different immunosuppressive regimens.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: anti-erythropoietin antibody; erythropoietin; pure red cell aplasia; renal transplantation; therapy

Document Type: Research Article

Affiliations: 1: Renal Division 2: Division of Haematology 3: Medical Clinica A, Department of Medicine, University Hospital, Zurich, Switzerland

Publication date: November 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more